{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:59:52Z","timestamp":1785542392013,"version":"3.56.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"35","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T00:00:00Z","timestamp":1562889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012479","name":"Weston Brain Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012479","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.vaccine.2019.07.044","type":"journal-article","created":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T20:15:21Z","timestamp":1563308121000},"page":"4920-4927","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Therapeutic vaccines for amyotrophic lateral sclerosis directed against disease specific epitopes of superoxide dismutase 1"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4445-8967","authenticated-orcid":false,"given":"Beibei","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Marciniuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebrima","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Yousefi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Napper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil R.","family":"Cashman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.vaccine.2019.07.044_b0005","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a024117","article-title":"Clinical spectrum of amyotrophic lateral sclerosis (ALS)","volume":"7","author":"Grad","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.vaccine.2019.07.044_b0010","first-page":"CD001447","article-title":"Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND)","volume":"3","author":"Miller","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"16","key":"10.1016\/j.vaccine.2019.07.044_b0015","doi-asserted-by":"crossref","first-page":"5976","DOI":"10.1073\/pnas.0305143101","article-title":"Dimer destabilization in superoxide dismutase may result in disease-causing properties: structures of motor neuron disease mutants","volume":"101","author":"Hough","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11\u201312","key":"10.1016\/j.vaccine.2019.07.044_b0020","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.bbadis.2006.05.004","article-title":"Structure, folding, and misfolding of Cu, Zn superoxide dismutase in amyotrophic lateral sclerosis","volume":"1762","author":"Rakhit","year":"2006","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.vaccine.2019.07.044_b0025","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1146\/annurev.biochem.72.121801.161647","article-title":"Copper-zinc superoxide dismutase and amyotrophic lateral sclerosis","volume":"74","author":"Valentine","year":"2005","journal-title":"Annu Rev Biochem"},{"issue":"6415","key":"10.1016\/j.vaccine.2019.07.044_b0030","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/362059a0","article-title":"Mutations in Cu\/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis","volume":"362","author":"Rosen","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2019.07.044_b0035","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1146\/annurev.neuro.27.070203.144244","article-title":"Unraveling the mechanisms involved in motor neuron degeneration in ALS","volume":"27","author":"Bruijn","year":"2004","journal-title":"Annu Rev Neurosci"},{"issue":"5","key":"10.1016\/j.vaccine.2019.07.044_b0040","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/j.1471-4159.2010.06683.x","article-title":"Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS","volume":"113","author":"Gros-Louis","year":"2010","journal-title":"J Neurochem"},{"issue":"10","key":"10.1016\/j.vaccine.2019.07.044_b0045","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1097\/NEN.0b013e3181f4a90a","article-title":"Induction of protective immunity by vaccination with wild-type apo superoxide dismutase 1 in mutant SOD1 transgenic mice","volume":"69","author":"Takeuchi","year":"2010","journal-title":"J Neuropathol Exp Neurol"},{"issue":"26","key":"10.1016\/j.vaccine.2019.07.044_b0050","doi-asserted-by":"crossref","first-page":"8791","DOI":"10.1523\/JNEUROSCI.5053-11.2012","article-title":"Targeting of monomer\/misfolded SOD1 as a therapeutic strategy for amyotrophic lateral sclerosis","volume":"32","author":"Liu","year":"2012","journal-title":"J Neurosci"},{"issue":"7","key":"10.1016\/j.vaccine.2019.07.044_b0055","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1073\/pnas.0606201104","article-title":"Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis","volume":"104","author":"Urushitani","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"22\u201324","key":"10.1016\/j.vaccine.2019.07.044_b0060","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1080\/15287394.2011.618967","article-title":"Generalization of the prion hypothesis to other neurodegenerative diseases: an imperfect fit","volume":"74","author":"Guest","year":"2011","journal-title":"J Toxicol Environ Health A"},{"key":"10.1016\/j.vaccine.2019.07.044_b0065","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev.biochem.75.101304.123901","article-title":"Protein misfolding, functional amyloid, and human disease","volume":"75","author":"Chiti","year":"2006","journal-title":"Annu Rev Biochem"},{"issue":"2","key":"10.1016\/j.vaccine.2019.07.044_b0070","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2217\/imt.10.3","article-title":"Immunotherapy for prion diseases: opportunities and obstacles","volume":"2","author":"Li","year":"2010","journal-title":"Immunotherapy"},{"key":"10.1016\/j.vaccine.2019.07.044_b0075","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/473706","article-title":"Evidence for prion-like mechanisms in several neurodegenerative diseases: potential implications for immunotherapy","volume":"2013","author":"Marciniuk","year":"2013","journal-title":"Clin Dev Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2019.07.044_b0080","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.vaccine.2009.10.134","article-title":"Design and delivery of a cryptic PrP(C) epitope for induction of PrP(Sc)-specific antibody responses","volume":"28","author":"Hedlin","year":"2010","journal-title":"Vaccine"},{"issue":"17","key":"10.1016\/j.vaccine.2019.07.044_b0085","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1016\/j.vaccine.2014.01.027","article-title":"Development of a multivalent, PrP(Sc)-specific prion vaccine through rational optimization of three disease-specific epitopes","volume":"32","author":"Marciniuk","year":"2014","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2019.07.044_b0090","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nsb935","article-title":"Amyloid-like filaments and water-filled nanotubes formed by SOD1 mutant proteins linked to familial ALS","volume":"10","author":"Elam","year":"2003","journal-title":"Nat Struct Biol"},{"issue":"3","key":"10.1016\/j.vaccine.2019.07.044_b0095","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/prot.20629","article-title":"Sequence and structural determinants of Cu, Zn superoxide dismutase aggregation","volume":"61","author":"Khare","year":"2005","journal-title":"Proteins"},{"key":"10.1016\/j.vaccine.2019.07.044_b0100","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jpcb.8b07680","article-title":"Prediction of misfolding-specific epitopes in SOD1 using collective coordinates","author":"Peng","year":"2018","journal-title":"J Phys Chem B"},{"issue":"14","key":"10.1016\/j.vaccine.2019.07.044_b0105","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1093\/bioinformatics\/btv136","article-title":"EpIC: a rational pipeline for epitope immunogenicity characterization","volume":"31","author":"Marciniuk","year":"2015","journal-title":"Bioinformatics"},{"issue":"1","key":"10.1016\/j.vaccine.2019.07.044_b0110","first-page":"101","article-title":"Carrier protein significantly alters the magnitude, duration, and type of antibody response to a peptide epitope from a self-protein","volume":"1","author":"Taschuk","year":"2015","journal-title":"J Immunol Vaccin"},{"issue":"1","key":"10.1016\/j.vaccine.2019.07.044_b0115","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0304-3940(02)01357-5","article-title":"Importance of IgG2c isotype in the immune response to beta-amyloid in amyloid precursor protein\/transgenic mice","volume":"338","author":"Petrushina","year":"2003","journal-title":"Neurosci Lett"},{"issue":"5","key":"10.1016\/j.vaccine.2019.07.044_b0120","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/j.1471-4159.2010.06979.x","article-title":"Neuronal over-expression of chromogranin A accelerates disease onset in a mouse model of ALS","volume":"115","author":"Ezzi","year":"2010","journal-title":"J Neurochem"},{"issue":"13","key":"10.1016\/j.vaccine.2019.07.044_b0125","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1097\/00001756-199709080-00012","article-title":"Quantitative motor assessment in FALS mice: a longitudinal study","volume":"8","author":"Barneoud","year":"1997","journal-title":"NeuroReport"},{"issue":"6990","key":"10.1016\/j.vaccine.2019.07.044_b0130","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature02544","article-title":"VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model","volume":"429","author":"Azzouz","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2019.07.044_b0135","unstructured":"Cashman NR, Ostermann JB, Chakrabartty A, Rakhit R. Methods and compositions to treat and detect misfolded-SOD1 mediated diseases. US Patent. 2011;12\/978,478 (2011\/0212097 A1)."},{"key":"10.1016\/j.vaccine.2019.07.044_b0140","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/978-1-4939-3387-7_37","article-title":"Methods and protocols for developing prion vaccines","volume":"1403","author":"Marciniuk","year":"2016","journal-title":"Methods Mol Biol"},{"issue":"39","key":"10.1016\/j.vaccine.2019.07.044_b0145","doi-asserted-by":"crossref","first-page":"16398","DOI":"10.1073\/pnas.1102645108","article-title":"Intermolecular transmission of superoxide dismutase 1 misfolding in living cells","volume":"108","author":"Grad","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2019.07.044_b0150","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1750-1326-8-46","article-title":"Features of wild-type human SOD1 limit interactions with misfolded aggregates of mouse G86R Sod1","volume":"8","author":"Qualls","year":"2013","journal-title":"Mol Neurodegener"},{"issue":"14","key":"10.1016\/j.vaccine.2019.07.044_b0155","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1073\/pnas.1419228112","article-title":"Structural and kinetic analysis of protein-aggregate strains in vivo using binary epitope mapping","volume":"112","author":"Bergh","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"issue":"37","key":"10.1016\/j.vaccine.2019.07.044_b0160","doi-asserted-by":"crossref","DOI":"10.1088\/0953-8984\/25\/37\/373101","article-title":"Modelling amyloid fibril formation kinetics: mechanisms of nucleation and growth","volume":"25","author":"Gillam","year":"2013","journal-title":"J Phys Condens Matter"},{"issue":"10","key":"10.1016\/j.vaccine.2019.07.044_b0165","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1529\/biophysj.106.098608","article-title":"A three-stage kinetic model of amyloid fibrillation","volume":"92","author":"Lee","year":"2007","journal-title":"Biophys J"},{"issue":"6","key":"10.1016\/j.vaccine.2019.07.044_b0170","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1172\/JCI84360","article-title":"Two superoxide dismutase prion strains transmit amyotrophic lateral sclerosis-like disease","volume":"126","author":"Bidhendi","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2019.07.044_b0175","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev.mi.37.100183.002233","article-title":"Synthetic peptide immunogens as vaccines","volume":"37","author":"Shinnick","year":"1983","journal-title":"Annu Rev Microbiol"},{"issue":"1","key":"10.1016\/j.vaccine.2019.07.044_b0180","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1073\/pnas.0811625106","article-title":"Constraining the loop, releasing prion infectivity","volume":"106","author":"Soto","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6815","key":"10.1016\/j.vaccine.2019.07.044_b0185","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/35050110","article-title":"A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease","volume":"408","author":"Janus","year":"2000","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.vaccine.2019.07.044_b0190","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00401-014-1256-4","article-title":"Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials","volume":"127","author":"Mandler","year":"2014","journal-title":"Acta Neuropathol"},{"issue":"6815","key":"10.1016\/j.vaccine.2019.07.044_b0195","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/35050116","article-title":"A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease","volume":"408","author":"Morgan","year":"2000","journal-title":"Nature"},{"issue":"6740","key":"10.1016\/j.vaccine.2019.07.044_b0200","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.vaccine.2019.07.044_b0205","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.pharmthera.2013.01.013","article-title":"Immunotherapy for neurodegenerative diseases: focus on alpha-synucleinopathies","volume":"138","author":"Valera","year":"2013","journal-title":"Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.vaccine.2019.07.044_b0210","doi-asserted-by":"crossref","first-page":"6980","DOI":"10.3390\/ijms12106980","article-title":"Protein misdirection inside and outside motor neurons in Amyotrophic Lateral Sclerosis (ALS): a possible clue for therapeutic strategies","volume":"12","author":"Ido","year":"2011","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.vaccine.2019.07.044_b0215","article-title":"Targeting Beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer's disease","volume":"2012","author":"Lobello","year":"2012","journal-title":"Int J Alzheimers Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2019.07.044_b0220","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1515\/REVNEURO.2010.21.4.273","article-title":"Antibody therapy in neurodegenerative disease","volume":"21","author":"Southwell","year":"2010","journal-title":"Rev Neurosci"},{"issue":"2","key":"10.1016\/j.vaccine.2019.07.044_b0225","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/YCO.0000000000000041","article-title":"Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?","volume":"27","author":"Panza","year":"2014","journal-title":"Curr Opin Psych"},{"issue":"3","key":"10.1016\/j.vaccine.2019.07.044_b0230","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1586\/1744666X.2014.883921","article-title":"Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward","volume":"10","author":"Panza","year":"2014","journal-title":"Exp Rev Clin Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2019.07.044_b0235","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1212\/01.WNL.0000148590.39911.DF","article-title":"Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease","volume":"64","author":"Masliah","year":"2005","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.vaccine.2019.07.044_b0240","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.coi.2004.07.012","article-title":"Current progress in beta-amyloid immunotherapy","volume":"16","author":"Schenk","year":"2004","journal-title":"Curr Opin Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2019.07.044_b0245","doi-asserted-by":"crossref","first-page":"203","DOI":"10.25100\/cm.v47i4.2640","article-title":"Amyloid-beta immunotherapy: the hope for Alzheimer disease?","volume":"47","author":"Barrera-Ocampo","year":"2016","journal-title":"Colomb Med (Cali)"},{"issue":"1","key":"10.1016\/j.vaccine.2019.07.044_b0250","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","article-title":"Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization","volume":"61","author":"Orgogozo","year":"2003","journal-title":"Neurology."},{"issue":"9","key":"10.1016\/j.vaccine.2019.07.044_b0255","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"issue":"7618","key":"10.1016\/j.vaccine.2019.07.044_b0260","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces Abeta plaques in Alzheimer's disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"issue":"45","key":"10.1016\/j.vaccine.2019.07.044_b0265","doi-asserted-by":"crossref","first-page":"30965","DOI":"10.1074\/jbc.M109.023945","article-title":"A common property of amyotrophic lateral sclerosis-associated variants: destabilization of the copper\/zinc superoxide dismutase electrostatic loop","volume":"284","author":"Molnar","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2019.07.044_b0270","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3389\/fncel.2013.00253","article-title":"An emerging role for misfolded wild-type SOD1 in sporadic ALS pathogenesis","volume":"7","author":"Rotunno","year":"2013","journal-title":"Front Cell Neurosci"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19309351?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19309351?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:37:44Z","timestamp":1759401464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19309351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":54,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0264410X19309351"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.07.044","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736227824.793579152","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic vaccines for amyotrophic lateral sclerosis directed against disease specific epitopes of superoxide dismutase 1","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.07.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}